(Q50791354)

19 March 2018

title

Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. (English)

1 reference

19 March 2018

0 references

4

Yehuda Shoenfeld

1 reference

19 March 2018

1

Uriel Katz

1 reference

19 March 2018

5

Anat Achiron

1 reference

19 March 2018

author name string

Irena Kishner

series ordinal

2

1 reference

19 March 2018

David Magalashvili

series ordinal

3

1 reference

19 March 2018

publication date

1 September 2006

1 reference

19 March 2018

published in

Autoimmunity

1 reference

19 March 2018

volume

39

1 reference

19 March 2018

issue

6

1 reference

19 March 2018

page(s)

513-517

1 reference

19 March 2018

Multiple Sclerosis Pathology: Evolution of Pathogenetic Concepts

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

Current approved options for treating patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

Intravenous immune globulins: an update for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

Intravenous immunoglobulin: adverse effects and safe administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

Complications of intravenous immune globulin treatment in neurologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

Intravenous immunoglobulin and the kidney--a two-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

Review: intravenous immunoglobulin therapy and thromboembolic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08916930600825867

10.1080/08916930600825867

21 January 2018

Identifiers

DOI

1 reference

19 March 2018

1 reference

19 March 2018